Press Releases

Forge Therapeutics and collaborators from Evotec and USC present new efficacy data at 2017 Keystone Symposia Conference

-Data demonstrates broad applicability for LpxC inhibitor in Acinetobacter baumannii, a life-threatening respiratory bacteria- LpxC antibiotic is Forge’s flagship program stemming from BLACKSMITH ...

Forge Therapeutics and collaborators from Evotec and USC present new efficacy data at 2017 Keystone Symposia Conference2017-10-31T01:12:48-07:00

Forge therapeutics announces participation in upcoming scientific and industry events

San Diego, California, October 24, 2017 – Forge Therapeutics, Inc. (Forge) announced today that the company will be participating in several scientific and ...

Forge therapeutics announces participation in upcoming scientific and industry events2017-10-24T00:35:50-07:00

Forge & Evotec expand strategic alliance with launch of BLACKSMITH Platform to discover novel metalloenzyme inhibitors across broad therapeutic areas

- BLACKSMITH Platform Initially Focused on the Development of Novel Classes of Antibiotics - - Expansion Highlights Significance of US-UK Biotech Partnerships –  ...

Forge & Evotec expand strategic alliance with launch of BLACKSMITH Platform to discover novel metalloenzyme inhibitors across broad therapeutic areas2017-10-12T15:06:06-07:00

Forge Therapeutics to participate in antimicrobial resistance panel at 2017 Bio Investor Forum

Forge Therapeutics to participate in antimicrobial resistance panel at 2017 Bio Investor Forum San Diego, California, October 11, 2017 – Forge Therapeutics, Inc., ...

Forge Therapeutics to participate in antimicrobial resistance panel at 2017 Bio Investor Forum2017-10-09T16:55:18-07:00

Forge Therapeutics to present at World Anti-Microbial Resistance Congress 2017

San Diego, California, September 12, 2017 – Forge Therapeutics, Inc., (Forge) announced today that the company will present a talk entitled, “Forging new ...

Forge Therapeutics to present at World Anti-Microbial Resistance Congress 20172017-10-04T14:16:36-07:00

Forge Therapeutics and Evotec present efficacy data for LpxC Inhibitor in urinary tract, lung, thigh, and abdominal infection models at ASM ESCMID 2017

San Diego, California, September 7, 2017 – Forge Therapeutics, Inc., (Forge) and its strategic alliance partner Evotec AG (Evotec), announced new preclinical data ...

Forge Therapeutics and Evotec present efficacy data for LpxC Inhibitor in urinary tract, lung, thigh, and abdominal infection models at ASM ESCMID 20172017-10-06T18:31:58-07:00

Forge Therapeutics and Evotec to present preclinical data on novel antibiotic program at 2017 ASM/ESCMID Conference

San Diego, California, August 29, 2017 – Forge Therapeutics, Inc., (Forge) and its strategic alliance partner Evotec AG (Evotec), announced today that the ...

Forge Therapeutics and Evotec to present preclinical data on novel antibiotic program at 2017 ASM/ESCMID Conference2017-10-04T14:17:29-07:00

Forge Therapeutics forms scientific advisory board with world renowned antibiotic and drug development experts

San Diego, California, July 26, 2017 – Forge Therapeutics, Inc., (Forge), a biotechnology company discovering first-in-class antibiotics using a breakthrough drug discovery platform, ...

Forge Therapeutics forms scientific advisory board with world renowned antibiotic and drug development experts2017-10-09T22:00:57-07:00

Forge Therapeutics to present at 2017 Bio International Convention

SAN DIEGO, California, June 12, 2017 – Forge Therapeutics, Inc., (Forge), a biotechnology company discovering first-in-class antibiotics using a breakthrough drug discovery platform, ...

Forge Therapeutics to present at 2017 Bio International Convention2017-10-09T17:02:15-07:00
Load More Posts
Go to Top